The effect of oxymetholone on the kidney tissues of one day old rats

Authors
Hojat Karimi Jashni
Shamsi Bandak
AmirAshkan Mahjoor
10.29252/jmj.9.3.2
Abstract
Introduction: Some of the athletes use oxymetholone as energy enhancer drug. Excessive consumption of oxymetholone leads to abnormalities such as lung cancer, ovarian cycle irregularities, liver cancer and adenoma in the renal tubules. This study aimed to investigate the effect of oxymetholone on the kidney tissues of the one day old rats. Material and methods: In this experimental study, 30 pregnant rats were divided into control, sham and experimental groups. For the experimental group, 10 mg oxymetholone and for the sham group 10 mg DMSO were injected intraperitoneally for 15 days. On the first day of delivery, the infants were weighted, and then dissected. Parameters such as weight, length, width and thickness of the kidneys were measured. Tissue sections were prepared and then examined under the microscope. The results were analyzed in SPSS software, using ANOVA test. Results: The results showed that the weight, length, width and thickness of the infants’ kidney, diameter of glomeruli, thickness of the cortex and medulla in the experimental group as compared with the control group had increased significantly (P <0.05). But the diameter between the glomerular space has decreased. Also, pathological changes such as glomerular cell proliferation, necrosis in the cortical tubules and cast forming in the tubules were observed. Conclusion: In this study, oxymetholone used caused pathologic changes on the renal tissue and increases the body weight and kidney weight in infant rats.
Keywords
Oxymetholone
Kidney
Tissues
1. Masse R, Bi H. Studies on anabolic steroids, GC/MS, characterization of unusual seco acidic metabolites of oxymetholone in human urine. J Steroid Biochem Mol Biol 1992; 42(2): 222-42. 2. Shahidi NT, Calantoff DV. The role of puberty in red cell production in hereditary haemolytic anemia. Br J Haematol 1969; 17(4): 335-42. 3. Barceló AC, Martínez MP, Conti MI‚ et al. Inability of oxymetholone to elicit an erythropoietin hyper secretory state in orchidectomised male mice. Comp Clin Pathol 2005; 13(4): 153-7. 4. Wilson JD, Androgens IN, Hardman JG, et al. Goodman and Gilman`s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996: 1441-57. 5. US Department of Health and Human Services, National Institute of Health. NTP technical report on the toxicology and carcinogenesis studies of oxymetholone (CAS NO. 434-07-1) IN F344/N Rats and toxicology studies of oxymetholone in B6C3F1 MICE. Accessed Jan. 1, 2011. Available from: http://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr485.pdf. 6. Christiansen K. Behavioural effects of androgen in men and women. J Endocr 2001; 170(1): 39-48. 7. Wright JE, Anabolic steroids and athletics. Exerc Sport Sci Rev 1980; 8: 149-202. 8. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23(9): 1355-90. 9. Mooradian AD, Morley JE, Korenman SG, Biological actions of androgens. Endocr Rev 1987; 8(1): 1-28. 10.Karila T, Karjalainen M, Mantysaari M, et al. Anabolic androgenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 2003; 24(5): 1-7. 11. Christiansen K. Behavioural effects of androgen in men and women . J Endocr 2001; 170: 39-48. 12. Collaer ML, Hines M. Human behavioral sex differences: A role for gonadal hormones during early development,Psychological bulletin. 1995; 118(1): 55-107. 13. Guyton AC, Hall JE. Textbook of medical physiology. 9th ed. Philadelphia: Saunders; 1996. 14. Nelson MA. Androgenic anabolic steroid use in adolescent. J. Pediatr Health Care 1989; 3(4): 175-80. 15. Johnson MD. Anabolic steroid use in adolescent athletes. Pediatr Clin North AM 1990; 37(5): 1111-23. 16.Hoseini L, Roozbeh J, Sagheb M, et al. Nandrolone decanoate increases the volume but not the length of the proximal and distal convoluted tubules of the mouse kidney. Micron 2009; 40(2): 226-30. 17. Antus B, Yao Y, Liu S, et al. Contribution of androgens to chronic allograft nephropathy is mediated by dihydrotestosterone. Kidney Int 2001; 60(5): 1955-63. 18. Deshmukh N, Petroczi A, Barker J, et al. Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids, Subst Treat Prev Policy 2010; 5: 7. 19. Brent J. Critical care toxicology. Diagnosis and management of the critically poisoned patient. Philadelphia: Elsevier; Mosby; 2005: 621-30.